Literature DB >> 2934317

Cleavage of the second component of complement by plasma proteases: implications in hereditary C1-inhibitor deficiency.

M A Smith, M A Kerr.   

Abstract

EDTA plasma from patients with hereditary angioedema (HAE), the genetic deficiency of C1-inhibitor, when incubated at 37 degrees produces a kinin-like activity which can induce contraction of oestrus rat uterus. The second component of complement (C2) has previously been suggested to be the source of this kinin-like activity, with the implication that C2-kinin is a normal product of complement activation. Our results show that purified human C2 is cleaved rapidly to C2a and C2b when added to HAE plasma, but not normal plasma or plasma from a danazol-treated HAE patient. However, the addition to HAE plasma of C2 at 20 X normal plasma concentration had no effect on the kinin activity generated on incubation at 37 degrees. In the presence of soya bean trypsin inhibitor, the rate of C2 cleavage and products were unaltered but no kinin activity was generated. C2 was cleaved by purified C1s to C2a and C2b. Incubation of C2 with trypsin resulted in cleavage to C2a and C2b followed by more extensive cleavage of both C2a and C2b. Kallikrein cleaved C2 to C2a and C2b but plasmin had no effect on C2. In no case was kinin activity generated. When C2 was cleaved by C1s to C2a and C2b then incubated with trypsin, kallikrein, or plasmin, no kinin activity was generated: only trypsin cleaved the C2 fragments further. The results suggest that C2 is not the source of the kinin-like activity generated in hereditary angioedema plasma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2934317      PMCID: PMC1453753     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  33 in total

1.  The purification and properties of the second component of human complement.

Authors:  M A Kerr; R R Porter
Journal:  Biochem J       Date:  1978-04-01       Impact factor: 3.857

2.  Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation.

Authors:  A D Schreiber; A P Kaplan; K F Austen
Journal:  J Clin Invest       Date:  1973-06       Impact factor: 14.808

3.  Immune hemolysis and the functional properties of the second (C2) and fourth (C4) components of complement. IV. Formation of EAC42 by treatment of C2 with trypsin in the presence of EAC4.

Authors:  M Loos; T Borsos; H J Rapp
Journal:  J Immunol       Date:  1972-09       Impact factor: 5.422

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Interaction of 125I-labelled complement subcomponents C-1r and C-1s with protease inhibitors in plasma.

Authors:  R B Sim; A Reboul; G J Arlaud; C L Villiers; M G Colomb
Journal:  FEBS Lett       Date:  1979-01-01       Impact factor: 4.124

6.  Interaction of C1-inhibitor with the C1r and C1s subcomponents in human C1.

Authors:  G J Arlaud; A Reboul; R B Sim; M G Colomb
Journal:  Biochim Biophys Acta       Date:  1979-01-25

7.  Hereditary angio-oedema: its pathogenesis and management.

Authors:  Z Ballogh; K Whaley
Journal:  Scott Med J       Date:  1980-07       Impact factor: 0.729

8.  Activation of the first component of human complement (C1) by antibody-antigen aggregates.

Authors:  A W Dodds; R B Sim; R R Porter; M A Kerr
Journal:  Biochem J       Date:  1978-11-01       Impact factor: 3.857

9.  Limited proteolysis of complement components C2 and factor B. Structural analogy and limited sequence homology.

Authors:  M A Kerr
Journal:  Biochem J       Date:  1979-12-01       Impact factor: 3.857

10.  Detection of active kallikrein in induced blister fluids of hereditary angioedema patients.

Authors:  J G Curd; L J Prograis; C G Cochrane
Journal:  J Exp Med       Date:  1980-09-01       Impact factor: 14.307

View more
  6 in total

Review 1.  Complement, Kinins, and Hereditary Angioedema: Mechanisms of Plasma Instability when C1 Inhibitor is Absent.

Authors:  Allen P Kaplan; Kusumam Joseph
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

2.  Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor.

Authors:  Eun D Han; Ryan C MacFarlane; Aideen N Mulligan; Jennifer Scafidi; Alvin E Davis
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

3.  Hereditary angioneurotic oedema: characterization of plasma kinin and vascular permeability-enhancing activities.

Authors:  L R Shoemaker; S J Schurman; V H Donaldson; A E Davis
Journal:  Clin Exp Immunol       Date:  1994-01       Impact factor: 4.330

Review 4.  Complement System Part I - Molecular Mechanisms of Activation and Regulation.

Authors:  Nicolas S Merle; Sarah Elizabeth Church; Veronique Fremeaux-Bacchi; Lubka T Roumenina
Journal:  Front Immunol       Date:  2015-06-02       Impact factor: 7.561

5.  Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children.

Authors:  Avner Reshef; Vesna Grivcheva-Panovska; Aharon Kessel; Shmuel Kivity; Maria Klimaszewska-Rembiasz; Dumitru Moldovan; Henriette Farkas; Vaclava Gutova; Stephen Fritz; Anurag Relan; Bruno Giannetti; Markus Magerl
Journal:  Pediatr Allergy Immunol       Date:  2019-05-29       Impact factor: 6.377

6.  Bradykinin and the pathogenesis of hereditary angioedema.

Authors:  Allen P Kaplan
Journal:  World Allergy Organ J       Date:  2011-04       Impact factor: 4.084

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.